SanofiSNY
SNY
About: Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Employees: 82,878
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
27% more call options, than puts
Call options by funds: $94.5M | Put options by funds: $74.6M
1.3% less ownership
Funds ownership: 22.21% [Q3] → 20.9% (-1.3%) [Q4]
4% less funds holding
Funds holding: 742 [Q3] → 709 (-33) [Q4]
13% less repeat investments, than reductions
Existing positions increased: 244 | Existing positions reduced: 279
15% less funds holding in top 10
Funds holding in top 10: 13 [Q3] → 11 (-2) [Q4]
17% less first-time investments, than exits
New positions opened: 75 | Existing positions closed: 90
21% less capital invested
Capital invested by funds: $16.2B [Q3] → $12.8B (-$3.49B) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$65
18%
upside
Avg. target
$65
18%
upside
High target
$65
18%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Goldman Sachs James Quigley 0 / 0 met price target | 18%upside $65 | Neutral Initiated | 21 Mar 2025 |
Financial journalist opinion
Based on 26 articles about SNY published over the past 30 days
Neutral
GlobeNewsWire
9 hours ago
Press Release: Annual General Meeting of April 30, 2025
Annual General Meeting of April 30, 2025 Approval of the financial statements for the fiscal year 2024 Distribution of a cash dividend of €3.92 per share, with payment as of May 14, 2025 Board composition: renewal of four Directors and ratification of the cooptation of Jean-Paul Kress Paris, April 30, 2025. The Combined General Shareholders' Meeting of Sanofi was held on April 30, 2025, under the chairmanship of Frédéric Oudéa.
Neutral
GlobeNewsWire
15 hours ago
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
Sanofi and CD&R close Opella transaction, creat e global consumer healthcare leader Paris, April 30, 2025 . Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in Sanofi's strategy.
Neutral
GlobeNewsWire
1 day ago
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
Neutral
GlobeNewsWire
1 day ago
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
Neutral
Seeking Alpha
6 days ago
Sanofi (SNY) Q1 2025 Earnings Call Transcript
Sanofi (NASDAQ:SNY ) Q4 2024 Earnings Call Transcript Q1 2025 Earnings Conference Call April 25, 2025 7:00 AM ET Company Participants Thomas Kudsk Larsen - Head, Investor Relations Paul Hudson - Chief Executive Officer François Roger - Executive Vice President, Chief Financial Officer Houman Ashrafian - Executive Vice President, Head of Research & Development Thomas Triomphe - Executive Vice President, Vaccines Brian Foard - Executive Vice President, Head of Specialty Care Conference Call Participants Richard Vosser - JPMorgan Luisa Hector - Berenberg Colleen Garvey - Guggenheim Ben Jackson - Jefferies Peter Verdult - BNP Exane Jo Walton - UBS Graham Parry - BofA James Quigley - Goldman Sachs Florent Cespedes - Bernstein Sarita Kapila - Morgan Stanley Simon Baker - Redburn Thomas Kudsk Larsen Hello everyone. This is Thomas Kudsk Larsen from the Sanofi IR team.
Positive
Zacks Investment Research
6 days ago
Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth
SNY beats Q1 estimates for earnings, while missing the same for sales. It expects earnings growth to rebound in 2025.
Positive
WSJ
6 days ago
Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug
The pharmaceutical company said the profit was driven by a higher gross margin and slower operating expense growth.
Positive
Reuters
6 days ago
Sanofi's quarterly profit beats estimates on Dupixent boost, newer products
France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its anti-inflammatory drug Dupixent, as well as newer treatments and vaccines.
Neutral
GlobeNewsWire
6 days ago
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER 1 and business EPS 2 of €1.79 Pharma launches reached sales of €0.8 billion, up 43.8%, driven by ALTUVIIIO Dupixent sales were €3.5 billion, up 20.3% Vaccines sales were €1.3 billion, up 11.4%, driven by favorable Beyfortus phasing Research and Development expenses reached €1.8 billion, up 6.9% Selling, general and administrative expenses were €2.2 billion, up 3.8% Business EPS was €1.79, up 15.7% at CER and up 17.0% reported; IFRS EPS was €1.52 Pipeline continued to deliver Six regulatory approvals across medicines in immunology, rare diseases, and oncology Recent new data from the mid-stage pipeline unlocks late-stage studies in asthma and skin diseases, broadening and deepening the scope in immunology Sustainability strategy Updated sustainability strategy focuses on access to healthcare, environmental impact, and resilience of healthcare systems. 70% of the portfolio and >75% of the pipeline target diseases that are impacted by climate and environmental challenges Capital allocation The closing of the sale of a controlling stake in Opella to CD&R is anticipated in Q23 Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager4 Guidance confirmed In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER5.
Neutral
Reuters
1 week ago
Novartis and Sanofi CEOs say EU should raise drug prices in face of tariffs
The European Union should allow drug prices to rise to U.S. levels in order to attract investment, the bosses of two European pharmaceutical giants said in a letter published in the Financial Times on Wednesday.
Charts implemented using Lightweight Charts™